JPWO2020176672A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020176672A5 JPWO2020176672A5 JP2021549538A JP2021549538A JPWO2020176672A5 JP WO2020176672 A5 JPWO2020176672 A5 JP WO2020176672A5 JP 2021549538 A JP2021549538 A JP 2021549538A JP 2021549538 A JP2021549538 A JP 2021549538A JP WO2020176672 A5 JPWO2020176672 A5 JP WO2020176672A5
- Authority
- JP
- Japan
- Prior art keywords
- drawings
- invention substantially
- substantially described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810698P | 2019-02-26 | 2019-02-26 | |
| US62/810,698 | 2019-02-26 | ||
| US201962825228P | 2019-03-28 | 2019-03-28 | |
| US62/825,228 | 2019-03-28 | ||
| PCT/US2020/019978 WO2020176672A1 (fr) | 2019-02-26 | 2020-02-26 | Polythérapies combinant des inhibiteurs de points de contrôle immunitaires activables et des anticorps activables conjugués |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523200A JP2022523200A (ja) | 2022-04-21 |
| JPWO2020176672A5 true JPWO2020176672A5 (fr) | 2023-03-03 |
Family
ID=69960745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549538A Pending JP2022523200A (ja) | 2019-02-26 | 2020-02-26 | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220233705A1 (fr) |
| EP (1) | EP3930761A1 (fr) |
| JP (1) | JP2022523200A (fr) |
| CN (1) | CN113677372A (fr) |
| WO (1) | WO2020176672A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60222B1 (sr) | 2015-05-04 | 2020-06-30 | Cytomx Therapeutics Inc | Anti-cd166 antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu |
| US20230408498A1 (en) * | 2020-10-13 | 2023-12-21 | Cz Biohub Sf, Llc | Compositions and methods involving antibody constructs |
| WO2023183888A1 (fr) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Constructions de protéines de liaison à l'antigène activables et leurs utilisations |
| WO2023183923A1 (fr) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Molécules masquées à double ancrage activables et leurs procédés d'utilisation |
| WO2023192973A1 (fr) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Molécules multispécifiques activables et leurs méthodes d'utilisation |
| WO2023192606A2 (fr) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Protéines de liaison au cd3 et leurs procédés d'utilisation |
| WO2024030843A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et leurs procédés d'utilisation |
| WO2024030850A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Substrats à protéase clivable et procédé d'utilisation associé |
| WO2024030847A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et procédés d'utilisation associés |
| WO2024030845A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et procédés d'utilisation associés |
| WO2024030858A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Substrats clivables par protéase et procédés d'utilisation associés |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| EP2535346B1 (fr) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Bibliothèques cellulaires de séquences peptidiques (CliPS) et procédés d'utilisation de celles-ci |
| WO2009025846A2 (fr) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci |
| CN106995495A (zh) | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| WO2010129609A2 (fr) | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | Anticorps et procédés d'utilisation de ceux-ci |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| WO2014026136A2 (fr) | 2012-08-10 | 2014-02-13 | Cytomx Therapeutics, Inc. | Systèmes résistant aux protéases pour présentation de polypeptides, leurs procédés de préparation et utilisation |
| CA2913732A1 (fr) * | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions et procedes permettant de conjuguer des anticorps activables |
| MX2017011644A (es) * | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| RS60222B1 (sr) * | 2015-05-04 | 2020-06-30 | Cytomx Therapeutics Inc | Anti-cd166 antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu |
| MX2018000621A (es) * | 2015-07-13 | 2018-05-11 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. |
| BR112019025188A2 (pt) * | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
-
2020
- 2020-02-26 JP JP2021549538A patent/JP2022523200A/ja active Pending
- 2020-02-26 US US17/433,295 patent/US20220233705A1/en active Pending
- 2020-02-26 WO PCT/US2020/019978 patent/WO2020176672A1/fr unknown
- 2020-02-26 CN CN202080027982.7A patent/CN113677372A/zh active Pending
- 2020-02-26 EP EP20714069.0A patent/EP3930761A1/fr active Pending